Washington

Quiénes somos

  • 5 de abril de 2022
    Estudio de la plataforma TAPISTRY (Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You)
  • 5 de abril de 2022
    Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
  • 5 de abril de 2022
    A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
  • 5 de abril de 2022
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
  • 5 de abril de 2022
    A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
  • 5 de abril de 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 5 de abril de 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 5 de abril de 2022
    Estudio de fase 3 de MRTX849 con cetuximab frente a quimioterapia en pacientes con cáncer colorrectal avanzado con mutación KRAS G12C (KRYSTAL-10)
  • 5 de abril de 2022
    Estudio de fase 1/2 de MRTX849 en pacientes con cáncer que presentan una mutación KRAS G12C KRYSTAL-1
  • 5 de abril de 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)